Marshall Wace
NMRA icon

Marshall Wace’s Neumora Therapeutics NMRA Stock Holding History

Marshall Wace’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Sell
904,458
-290,852
-24% -$554K ﹤0.01% 1993
2026
Q1 		$2.33M Buy
1,195,310
+611,552
+105% +$1.58M ﹤0.01% 1699
2025
Q4 		$1.04M Buy
+583,758
New +$1.28M ﹤0.01% 1901
2025
Q3 		– Sell
-250,490
Closed -$183K – 3231
2025
Q2 		$183K Buy
+250,490
New +$190K ﹤0.01% 2472
2024
Q3 		– Sell
-134,545
Closed -$1.32M – 2817
2024
Q2 		$1.32M Buy
+134,545
New +$1.39M ﹤0.01% 1556
2023
Q4 		– Sell
-256,412
Closed -$3.62M – 2470
2023
Q3 		$3.62M Buy
+256,412
New +$3.2M 0.01% 992

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace's NMRA Position: Q2 2026 in Review

Marshall Wace reduced its Neumora Therapeutics (NMRA) stake by 24% in Q2 2026, selling an estimated $554K and leaving 904,458 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1993.

Marshall Wace first reported a position in NMRA in Q3 2023 and has held it in 6 quarters since. The position peaked at $3.62M in Q3 2023. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Marshall Wace held 904,458 shares of Neumora Therapeutics worth $1.54M as of Q2 2026.
  • Marshall Wace sold 290,852 Neumora Therapeutics shares in Q2 2026, an estimated $554K.
  • Neumora Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1993 holding.
  • Marshall Wace first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 6 quarters since.
  • Marshall Wace's Neumora Therapeutics position peaked at $3.62M in Q3 2023.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.